AU2003295561A1 - Inhibitory oliogonucleotides targeted to bcl-2 - Google Patents
Inhibitory oliogonucleotides targeted to bcl-2 Download PDFInfo
- Publication number
- AU2003295561A1 AU2003295561A1 AU2003295561A AU2003295561A AU2003295561A1 AU 2003295561 A1 AU2003295561 A1 AU 2003295561A1 AU 2003295561 A AU2003295561 A AU 2003295561A AU 2003295561 A AU2003295561 A AU 2003295561A AU 2003295561 A1 AU2003295561 A1 AU 2003295561A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- oligonucleotide
- oligonucleotides
- bcl
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42626902P | 2002-11-14 | 2002-11-14 | |
| US60/426,269 | 2002-11-14 | ||
| PCT/US2003/036614 WO2004046327A2 (en) | 2002-11-14 | 2003-11-14 | Inhibitory oliogonucleotides targeted to bcl-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003295561A1 true AU2003295561A1 (en) | 2004-06-15 |
Family
ID=32326325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003295561A Abandoned AU2003295561A1 (en) | 2002-11-14 | 2003-11-14 | Inhibitory oliogonucleotides targeted to bcl-2 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7256284B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1572970A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006514546A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003295561A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2505680A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004046327A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| US20050287667A1 (en) * | 2004-06-01 | 2005-12-29 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| JP5122474B2 (ja) | 2005-12-01 | 2013-01-16 | プロネイ・セラピューティクス・インコーポレイテッド | 両性リポソーム製剤 |
| WO2009071681A2 (en) * | 2007-12-07 | 2009-06-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of bcl-2 |
| EP2350296A4 (en) * | 2008-11-17 | 2013-04-03 | Enzon Pharmaceuticals Inc | BRANCHED CATIONIC LIPIDS FOR THE SYSTEM FOR INTRODUCING NUCLEIC ACIDS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5734033A (en) * | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
| US5831066A (en) * | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
| US5605798A (en) * | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US5912147A (en) * | 1996-10-22 | 1999-06-15 | Health Research, Inc. | Rapid means of quantitating genomic instability |
| US6041181A (en) * | 1997-07-23 | 2000-03-21 | International Business Machines Corporation | Method of, system for, and computer program product for providing quick fusion in WHERE constructs |
| US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| DE69938128D1 (de) * | 1998-03-28 | 2008-03-27 | Univ Utah Res Found | Zielgerichtete antisense-bibliotheken |
| KR20020013519A (ko) * | 1999-04-08 | 2002-02-20 | 추후제출 | 보편적 및/또는 축퇴성 염기를 포함하는 안티센스올리고뉴클레오티드 |
| US6310047B1 (en) * | 1999-08-24 | 2001-10-30 | Virginia Commonwealth University | High affinity DNA binding compounds as adjuvants in antisense technology |
| US7056653B2 (en) * | 2000-02-10 | 2006-06-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Detection of binding of charged species using PH- or potential-sensitive probes |
| US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| US7060690B2 (en) * | 2001-01-22 | 2006-06-13 | Genta Incorporated | Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof |
-
2003
- 2003-11-14 AU AU2003295561A patent/AU2003295561A1/en not_active Abandoned
- 2003-11-14 US US10/714,310 patent/US7256284B2/en not_active Expired - Fee Related
- 2003-11-14 EP EP03786757A patent/EP1572970A4/en not_active Withdrawn
- 2003-11-14 WO PCT/US2003/036614 patent/WO2004046327A2/en not_active Ceased
- 2003-11-14 CA CA002505680A patent/CA2505680A1/en not_active Abandoned
- 2003-11-14 JP JP2004553781A patent/JP2006514546A/ja active Pending
-
2007
- 2007-07-12 US US11/827,995 patent/US20080096835A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7256284B2 (en) | 2007-08-14 |
| JP2006514546A (ja) | 2006-05-11 |
| WO2004046327A2 (en) | 2004-06-03 |
| EP1572970A2 (en) | 2005-09-14 |
| WO2004046327A3 (en) | 2005-12-29 |
| CA2505680A1 (en) | 2004-06-03 |
| EP1572970A4 (en) | 2006-11-15 |
| US20040152654A1 (en) | 2004-08-05 |
| US20080096835A1 (en) | 2008-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240360452A1 (en) | Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53 | |
| EP2850186B1 (en) | Compositions and methods for modulating smn gene family expression | |
| EP3400948B1 (en) | Methods and means for efficient skipping of at least exon 52 of the human duchenne muscular dystrophy gene | |
| US20150247145A1 (en) | Methods for modulating rna using 3' targeting oligonucleotides | |
| WO2023171820A1 (ja) | キャリアペプチドが連結された核酸 | |
| EA038478B1 (ru) | Композиции и способы для ингибирования генной экспрессии лпа | |
| KR20110017005A (ko) | Tgf-베타 수용체 유전자 발현 억제용 조성물 및 방법 | |
| JP7634542B2 (ja) | B型肝炎ウイルス感染症を処置するためのsept9阻害剤の使用 | |
| US20230118138A1 (en) | Use of scamp3 inhibitors for treating hepatitis b virus infection | |
| US20080096835A1 (en) | Inhibitory oligonucleotides targeted to BCL-2 | |
| US20240294907A1 (en) | Selective delivery of oligonucleotides to glial cells | |
| JP2025094072A (ja) | B型肝炎ウイルス感染を処置するためのcops3阻害剤の使用 | |
| WO2021122993A1 (en) | Use of saraf inhibitors for treating hepatitis b virus infection | |
| WO2004035759A2 (en) | Inhibitory oligonucleotides targeted to matrix metalloproteinase-9 | |
| WO2025254047A1 (ja) | アンドロゲン受容体 rna配列に基づく新規二本鎖rna及びその利用 | |
| WO2026048822A1 (ja) | Mapt rna配列に基づく新規二本鎖rna及びその利用 | |
| WO2025103457A1 (zh) | 抑制LPA表达的siRNA及其用途 | |
| HK40071185A (en) | Use of sept9 inhibitors for treating hepatitis b virus infection | |
| CN122070363A (zh) | 靶向转甲状腺素蛋白的寡核苷酸及其用途 | |
| BR112018006489B1 (pt) | Agente de interferência de rna (rnai) da lipoproteína a (lpa), seus usos e composição farmacêutica | |
| HK1262582B (en) | Methods and means for efficient skipping of at least exon 52 of the human duchenne muscular dystrophy gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |